Skip to main content

Table 3 Role of PSA at the first follow-up in the subgroup of UIR patients

From: Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy

 

HR

95%CI

p-value

bRFS

   

First Follow-up PSA (<0,7 vs. ≥0,7)

0,19

0,07–0,59

<0,01

LF

   

First Follow-up PSA (<0,7 vs. ≥0,7)

0,27

0,08–0,96

0,04

MFS

   

First Follow-up PSA (<0,7 vs. ≥0,7)

0,14

0,02–0,86

0,03